Sarah Cannon and Genospace, LLC Announce Merger to Enhance Cancer Care Through Personalized Medicine Platform

Nashville, Tenn. and Cambridge, Mass., January 12, 2017 - Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA), today announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.

Read More

Genospace Announces Launch of Trial Match, a Mobile Clinical Trial Matching Application

CAMBRIDGE, MA — October 25, 2016 — Genospace, a leading data analytics platform serving the healthcare and life sciences industry, today announced the launch of Genospace Trial Match. The newly launched mobile application enables real-time clinical trial matching at the point of care based on molecular profiling and clinical data.

Read More

Genospace Partner Sequence Bio Announces Initiative with Government of Newfoundland and Labrador on Large-Scale Precision Medicine Initiative

CAMBRIDGE, MA, October 15, 2015 — Genospace, a precision medicine software company that has developed a comprehensive suite of tools enabling the broad use of genomic and other biomedical data in research and clinical care, today announced that Sequence Bioinformatics, Inc. and the Government of Newfoundland and Labrador have selected Genospace Population Analytics™ to support a groundbreaking precision medicine initiative.

Read More

Genospace Expands Board With Appointment of New Advisors

CAMBRIDGE, MA, July 22, 2015 — GenoSpace, a provider of cloud-based software solutions for the interpretation and analysis of genomic and other biomedical data, today announced the appointment of three prominent executives to its business advisory board. The following individuals will join current advisor Joseph Donahue, Senior Vice President of Commercial Collaborations and Innovation at BioReference Laboratories, in helping drive the overall growth of GenoSpace and its mission to serve customers in research, clinical development, pathology and clinical care.

Read More

Inova Health System Selects Genospace Population Analytics

CAMBRIDGE, MA, February 11, 2015 — GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools enabling the broad use of genomic and other biomedical data in research and clinical care, today announced that Inova Health System has selected GenoSpace Population Analytics™ to support a groundbreaking whole-genome sequencing initiative. Inova is a not-for-profit health care system based in the Washington, D.C. metropolitan area that serves more than two million people.

Read More

Genospace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories

CAMBRIDGE, MA, September 23, 2014 — GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to enable enhanced data access and cohort construction for biorepositories.

Read More

Caris Life Sciences Collaborates with Genospace to Enhance Data Mining Capabilities to Advance the Molecular Understanding of Cancer

Irving, TX, Aug. 14, 2014 – Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced a collaboration with GenoSpace, a Massachusetts-based technology company that develops robust software solutions for genomic and health data.  Caris will apply GenoSpace’s population analytics offerings to uncover and better utilize key insights from the company’s industry-leading tumor profiling service, Caris Molecular Intelligence™. The partnership also leverages GenoSpace’s analytics architecture expertise to unlock key treatment insights from the Caris Registry™, a database of clinicopathologic and outcome variables from consenting patients whose tumors underwent multi-technology profiling by Caris.

Read More

Genospace Announces Strategic Investment by Thomson Reuters

CAMBRIDGE, MA, August 12, 2014 — GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it completed a financing deal with Thomson Reuters, the world leader in providing intelligent information for businesses and professionals. GenoSpace will use the funds to accelerate expansion of its customer base in research, clinical development, laboratory medicine and clinical care. The funding marks the first investment in the precision medicine informatics market by Thomson Reuters.

Read More

PathGroup Expands SmartGenomics Offering to Include Profiling of Hematologic Malignancies

BRENTWOOD, Tenn. – PathGroup, one of the largest private providers of pathology services in the United States, today announced launch of the SmartGenomics™ Heme Profile, which provides genomic profiling and information for patients that have failed or been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas and myeloproliferative/myelodysplastic diseases. The newly launched offering is based on collaboration between PathGroup, GenoSpace and the IP & Science business of Thomson Reuters.

Read More

Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition Between Genospace, PathGroup & Thomson Reuters

CAMBRIDGE, MA, August 13, 2013 — GenoSpace, PathGroup and the IP & Science business of Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients. 

Read More

White House to Honor John Quackenbush, PhD, as an Open Science Champion of Change

WASHINGTON, DC – On Thursday, June 20th, the White House will honor 13 leaders and organizations promoting and using open scientific data and publications to accelerate progress and improve our world. As entrepreneurs, academics, and researchers, these Champions of Change have made an impact across disciplines – from archeology to biomedical research, and from the humanities to astronomy. At the event, these Champions will highlight initiatives that are helping make “open” the default in scientific research.

Read More

The Multiple Myeloma Research Foundation (MMRF) and Genospace Partner to Launch Groundbreaking Information Ecosystem

NORWALK, CT & CAMBRIDGE, MA, November 29, 2012 —The Multiple Myeloma Research Foundation (MMRF), a non-profit organization dedicated to accelerating research and the development of improved therapeutics leading to a cure for multiple myeloma, and GenoSpace, a Cambridge, Massachusetts-based bioinformatics company, today announced a partnership to create a revolutionary information ecosystem that can be utilized by researchers, clinicians and patients to drive discoveries in multiple myeloma. This partnership will create a first-in-class, publicly shared database comprised of a researcher gateway to access data from the landmark MMRF CoMMpassSM (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profiles) Study and a patient gateway to enable access to real-time clinical and community support. Centralizing such considerable multiple myeloma patient data may accelerate discovery of individualized treatment approaches, biomarkers, diagnostics and new drug targets.

Read More

Genospace Joins Thomson Reuters Life Sciences Partner Ecosystem

CAMBRIDGE, MA, August 12, 2012 — The Intellectual Property & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, today announced that GenoSpace joined its Life Sciences Partner Ecosystem. The companies will work together to develop an integrated product offering for the analysis and interpretation of human genomic variation.

Read More